Clinical Trial: Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy

U.S., Nov. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07918079) titled 'Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy' on Nov. 01.

Brief Summary: Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy

Study Start Date: Nov. 02

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: Netupitant and Palonosetron

Oral fixed-dose netupitant/palonosetron (NEPA) capsule (300 mg netupitant / 0.5 mg palonosetron), 1 capsule administered orally.

DRUG: Dexamethasone

Dexamethasone 12 mg administered orally or intravenously on Day 1, , followed by 8 mg orally or intravenously once daily on Days 2-4. No dexamethas...